Sanjivani Paranteral Ltd

Sanjivani Paranteral Fund Raise

Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.

Sanjivani Paranteral Annual General Meeting

Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.

Sanjivani Paranteral Investor Presentation: Key Takeaways

Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.

Call

Guides 110% growth

Sanjivani Paranteral Q1 FY27 Results: Net Profit ₹2.5 Cr, Up 47.1% YoY

Sanjivani Paranteral Ltd reported revenue from operations of ₹23.8 Cr (+33.0% YoY) and net profit of ₹2.5 Cr (+47.1% YoY) for Q1 FY27.

Key figure

Net profit ₹2.5 Cr · +47.1% YoY

Sanjivani Paranteral Earnings Call: Key Takeaways

Sanjivani Paranteral Q4 FY26 earnings transcript. Management transitions to a multi-vertical platform with base formulation business and new IVF and nutraceutical ventures.

Sanjivani Paranteral Earnings Call: Key Takeaways

Sanjivani Paranteral's Q4 & FY26 presentation shows significant decline in standalone financials. Focus remains on injectables (53.5% FY26 revenue) and export markets (78.5% FY26 revenue).

Sanjivani Paranteral Q4 FY26 Results: Net Profit ₹0.5 Cr, Down 77.3% YoY

Sanjivani Paranteral Ltd reported revenue from operations of ₹13.2 Cr (-27.5% YoY) and net profit of ₹0.5 Cr (-77.3% YoY) for Q4 FY26.

Key figure

Net profit ₹0.5 Cr · -77.3% YoY